Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH Highlights
Filter by Topic
ASH 2011 Annual Meeting
ASH 2013 Annual Meeting
ASH 2014 - Castleman's Disease
ASH 2014 - CLL
ASH 2015 - Multiple Myeloma
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
ASH 2015 – Leukemia
ASH 2017
ASH 2017 - Acute Myeloid Leukemia
ASH 2019 Wrap-up
Idelalisib plus Rituximab for Relapsed CLL: Interim Analysis in Subpopulations with del17p and Other Adverse Prognostic Factors
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
The RESONATE-17 Trial: Efficacy and Safety of Ibrutinib in Patients with Relapsed/Refractory CLL and del17p
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
Interim Analysis of Phase 2 ICLL01: Ofatumumab and High-Dose Methylprednisolone in Patients at Highest Risk for Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
ONO-4059: A New Oral, Selective BTK Inhibitor for Patients with High-Risk CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
Results from the CLL11 Study: Salvage Therapy with Obinutuzumab plus Chlorambucil in Patients with CLL and Comorbidities
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
Dose De-Escalation in Fit, Older Patients with CLL: Balancing Efficacy, Safety, and Tolerability
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
Read Article
Page 11 of 15
6
7
8
9
10
11
12
13
14
15
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma